The trial design is aggressive, but apparently mortality endpoint will be met by leronlimab.

Mesoblast designed a trial without apparently any deep analysis of their purported MOA, just had EINDs with case matching in a separate hospital.

Cytodyn eind results substantially more impressive and validated as well as one could hope by Dr Patterson’s analysis.

The increasingly positive DSMB analyses strongly argue for mortality endpoint being met